Immix Biopharma | Investor Presentation Deck | 64 slides · page 33 of 64
The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.
Deck · competitive_analysis · compare_peers · dense density
Slide locked Sign in to view
Slide schematic 4/4
callout 1/1 source-note 1/1 table 1/1 title 1/1
Components 4
primary source-note data headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1